|
1
|
Jemal A, Ward EM, Johnson CJ, Cronin KA,
Ma J, Ryerson B, Mariotto A, Lake AJ, Wilson R, Sherman RL, et al:
Annual Report to the Nation on the Status of Cancer, 1975–2014,
Featuring Survival. J Natl Cancer Inst. 109:djx0302017. View Article : Google Scholar :
|
|
2
|
Zini A, Czerninski R and Sgan-Cohen HD:
Oral cancer over four decades: Epidemiology, trends, histology, and
survival by anatomical sites. J Oral Pathol Med. 39:299–305. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yadav P: Recent advances in head and neck
cancer reconstruction. Indian J Plast Surg. 47:185–190. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Maniotis AJ, Folberg R, Hess A, Seftor EA,
Gardner LM, Pe'er J, Trent JM, Meltzer PS and Hendrix MJ: Vascular
channel formation by human melanoma cells in vivo and in vitro:
Vasculogenic mimicry. Am J Pathol. 155:739–752. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang S, Zhang D and Sun B: Vasculogenic
mimicry: Current status and future prospects. Cancer Lett.
254:157–164. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
van der Schaft DW, Seftor RE, Seftor EA,
Hess AR, Gruman LM, Kirschmann DA, Yokoyama Y, Griffioen AW and
Hendrix MJ: Effects of angiogenesis inhibitors on vascular network
formation by human endothelial and melanoma cells. J Natl Cancer
Inst. 96:1473–1477. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Xiang D, Yuan Y, Chen L, Liu X, Belani C
and Cheng H: Niclosamide, an anti-helminthic molecule,
downregulates the retroviral oncoprotein Tax and pro-survival Bcl-2
proteins in HTLV-1-transformed T lymphocytes. Biochem Biophys Res
Commun. 464:221–228. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen W, Mook RA Jr, Premont RT and Wang J:
Niclosamide: Beyond an antihelminthic drug. Cell Signal Apr.
4:2017(Epub ahead of print).
|
|
10
|
Li Y, Li PK, Roberts MJ, Arend RC, Samant
RS and Buchsbaum DJ: Multi-targeted therapy of cancer by
niclosamide: A new application for an old drug. Cancer Lett.
349:8–14. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Djebali S, Davis CA, Merkel A, Dobin A,
Lassmann T, Mortazavi A, Tanzer A, Lagarde J, Lin W, Schlesinger F,
et al: Landscape of transcription in human cells. Nature.
489:101–108. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Martens-Uzunova ES, Böttcher R, Croce CM,
Jenster G, Visakorpi T and Calin GA: Long noncoding RNA in
prostate, bladder, and kidney cancer. Eur Urol. 65:1140–1151. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li M, Marin-Muller C, Bharadwaj U, Chow
KH, Yao Q and Chen C: MicroRNAs: Control and loss of control in
human physiology and disease. World J Surg. 33:667–684. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhao Y, Ling Z, Hao Y, Pang X, Han X,
Califano JA, Shan L and Gu X: MiR-124 acts as a tumor suppressor by
inhibiting the expression of sphingosine kinase 1 and its
downstream signaling in head and neck squamous cell carcinoma.
Oncotarget. 8:25005–25020. 2017.PubMed/NCBI
|
|
15
|
Chen SM, Chou WC, Hu LY, Hsiung CN, Chu
HW, Huang YL, Hsu HM, Yu JC and Shen CY: The effect of MicroRNA-124
overexpression on anti-tumor drug sensitivity. PLoS One.
10:e01284722015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wan HY, Li QQ, Zhang Y, Tian W, Li YN, Liu
M, Li X and Tang H: MiR-124 represses vasculogenic mimicry and cell
motility by targeting amotL1 in cervical cancer cells. Cancer Lett.
355:148–158. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chiang HR, Schoenfeld LW, Ruby JG, Auyeung
VC, Spies N, Baek D, Johnston WK, Russ C, Luo S, Babiarz JE, et al:
Mammalian microRNAs: Experimental evaluation of novel and
previously annotated genes. Genes Dev. 24:992–1009. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
DiMasi JA, Hansen RW and Grabowski HG: The
price of innovation: New estimates of drug development costs. J
Health Econ. 22:151–185. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chong CR and Sullivan DJ Jr: New uses for
old drugs. Nature. 448:645–646. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang JY, Sun T, Zhao XL, Zhang SW, Zhang
DF, Gu Q, Wang XH, Zhao N, Qie S and Sun BC: Functional
significance of VEGF-a in human ovarian carcinoma: Role in
vasculogenic mimicry. Cancer Biol Ther. 7:758–766. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jones MK, Szabó IL, Kawanaka H, Husain SS
and Tarnawski AS: von Hippel Lindau tumor suppressor and
HIF-1alpha: New targets of NSAIDs inhibition of hypoxia-induced
angiogenesis. FASEB J. 16:264–266. 2002.PubMed/NCBI
|
|
22
|
Feltrin D and Pertz O: Assessment of Rho
GTPase signaling during neurite outgrowth. Methods Mol Biol.
827:181–194. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kwon J, Kim NH and Choi I: ROCK activity
regulates functional tight junction assembly during blastocyst
formation in porcine parthenogenetic embryos. PeerJ. 4:e19142016.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang JG, Li XY, Wang YZ, Zhang QD, Gu SY,
Wu X, Zhu GH, Li Q and Liu GL: ROCK is involved in vasculogenic
mimicry formation in hepatocellular carcinoma cell line. PLoS One.
9:e1076612014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xia Y, Cai X, Fan J, Zhang L, Li Z, Ren J,
Wu G and Zhu F: RhoA/ROCK pathway inhibition by fasudil suppresses
the vasculogenic mimicry of U2OS osteosarcoma cells in vitro.
Anticancer Drugs. 28:514–521. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Maes H, Van Eygen S, Krysko DV,
Vandenabeele P, Nys K, Rillaerts K, Garg AD, Verfaillie T and
Agostinis P: BNIP3 supports melanoma cell migration and
vasculogenic mimicry by orchestrating the actin cytoskeleton. Cell
Death Dis. 5:e11272014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen Z and Han ZC: STAT3: A critical
transcription activator in angiogenesis. Med Res Rev. 28:185–200.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhu W, Sun W, Zhang JT, Liu ZY, Li XP and
Fan YZ: Norcantharidin enhances TIMP-2 anti-vasculogenic mimicry
activity for human gallbladder cancers through downregulating MMP-2
and MT1-MMP. Int J Oncol. 46:627–640. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wu F, Chen Y, Li Y, Ju J, Wang Z and Yan
D: RNA-interference-mediated Cdc42 silencing down-regulates
phosphorylation of STAT3 and suppresses growth in human
bladder-cancer cells. Biotechnol Appl Biochem. 49:121–128. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yu H and Jove R: The STATs of cancer - new
molecular targets come of age. Nat Rev Cancer. 4:97–105. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Valdembri D, Serini G, Vacca A, Ribatti D
and Bussolino F: In vivo activation of JAK2/STAT-3 pathway during
angiogenesis induced by GM-CSF. FASEB J. 16:225–227.
2002.PubMed/NCBI
|
|
32
|
Osugi T, Oshima Y, Fujio Y, Funamoto M,
Yamashita A, Negoro S, Kunisada K, Izumi M, Nakaoka Y, Hirota H, et
al: Cardiac-specific activation of signal transducer and activator
of transcription 3 promotes vascular formation in the heart. J Biol
Chem. 277:6676–6681. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Song YY, Sun LD, Liu ML, Liu ZL, Chen F,
Zhang YZ, Zheng Y and Zhang JP: STAT3, p-STAT3 and HIF-1α are
associated with vasculogenic mimicry and impact on survival in
gastric adenocarcinoma. Oncol Lett. 8:431–437. 2014.PubMed/NCBI
|
|
34
|
Hu A, Huang JJ, Jin XJ, Li JP, Tang YJ,
Huang XF, Cui HJ, Xu WH and Sun GB: Curcumin suppresses
invasiveness and vasculogenic mimicry of squamous cell carcinoma of
the larynx through the inhibition of JAK-2/STAT-3 signaling
pathway. Am J Cancer Res. 5:278–288. 2014.PubMed/NCBI
|
|
35
|
Chiablaem K, Lirdprapamongkol K,
Keeratichamroen S, Surarit R and Svasti J: Curcumin suppresses
vasculogenic mimicry capacity of hepatocellular carcinoma cells
through STAT3 and PI3K/AKT inhibition. Anticancer Res.
34:1857–1864. 2014.PubMed/NCBI
|
|
36
|
Qureshi IA and Mehler MF: Regulation of
non-coding RNA networks in the nervous system - what's the REST of
the story? Neurosci Lett. 466:73–80. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Carroll AP, Tooney PA and Cairns MJ:
Context-specific microRNA function in developmental complexity. J
Mol Cell Biol. 5:73–84. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kozomara A and Griffiths-Jones S: miRBase:
Annotating high confidence microRNAs using deep sequencing data.
Nucleic Acids Res. 42(Database issue): D68–73. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Jin L, Miao J, Liu Y, Li X, Jie Y, Niu Q
and Han X: Icaritin induces mitochondrial apoptosis by
up-regulating miR-124 in human oral squamous cell carcinoma cells.
Biomed Pharmacother. 85:287–295. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Li Y, Zhang Z, Liu X, Huang T, He W, Shen
Y, Liu X, Hong K and Cao Q: miR-124 functions as a tumor suppressor
in the endometrial carcinoma cell line HEC-1B partly by suppressing
STAT3. Mol Cell Biochem. 388:219–231. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lu Y, Yue X, Cui Y, Zhang J and Wang K:
MicroRNA-124 suppresses growth of human hepatocellular carcinoma by
targeting STAT3. Biochem Biophys Res Commun. 441:873–879. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhang J, Lu Y, Yue X, Li H, Luo X, Wang Y,
Wang K and Wan J: MiR-124 suppresses growth of human colorectal
cancer by inhibiting STAT3. PLoS One. 8:e703002013. View Article : Google Scholar : PubMed/NCBI
|
